Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rossing P, Scott C, Gay A, et al
Adding CJC-1295 to a sermorelin protocol provides baseline GHRH receptor stimulation between sermorelin's bedtime pulses
In this context, the functional mimicry of GLP-1 should be considered worthwhile if the designed agonist can act as a biased agonist of GLP-1R, selectively triggering anti-inflammatory signaling pathways that can aid in reducing the growth and differentiation of certain types of neuroendocrine tumors
RELATED: Trump says GLP-1 weight-loss drugs coming at $50 for Medicare patients The Trump administration had said that coverage of the drugs for obesity will expand to Medicare patients starting next year, but Trump announced May 2 that Zepbound and Wegovy would be available to Medicare patients for $50 a month starting July 1